Clinical Laserthermia Systems AB Class B (CLS.B) AI Stock Analysis

• Market Cap: €174.53M
• Dividend Yield: N/A
• Average Volume (3M): 287.83K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: 57.14%
• EPS Growth: 81.07%
• Country: SE
• Employees: 17
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Devices
• EPS (TTM): -0.25
• Shares Outstanding: 25,663,593
• 10 Day Avg. Volume: 173,691
• 30 Day Avg. Volume: 287,831
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €6.56
• Price Target Upside: -2.76% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 53 Neutral
• Price Target: kr6.50 ▼(-3.70% Downside)

The stock score reflects a mix of robust revenue growth and strong technical momentum countered by significant profitability challenges and negative valuation metrics. The company's financial performance highlights the need for improved margins and sustainable cash flow, while technical analysis suggests potential for short-term gains despite valuation concerns.

Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model

Company Description

Clinical Laserthermia Systems AB Class B (CLS.B) is a Swedish medical technology company specializing in innovative cancer treatment solutions. The company operates in the healthcare sector and is focused on developing and commercializing advanced laser-based systems for minimally invasive thermal treatment of cancerous tumors. CLS.B's core product, the TRANBERG® Thermal Therapy System, employs laser-induced thermotherapy (LITT) to target and destroy cancer cells while preserving surrounding healthy tissue, offering a promising alternative to traditional surgical methods.

How the Company Makes Money

Clinical Laserthermia Systems AB makes money primarily through the sale and distribution of its TRANBERG® Thermal Therapy System and related consumables. Revenue is generated from direct sales to hospitals and clinics, as well as through partnerships with medical distributors and healthcare providers. The company may also earn income from licensing agreements or collaborations with research institutions and medical technology companies. Additionally, ongoing customer support, training services, and maintenance contracts provide recurring revenue streams. Strategic partnerships and clinical trials contribute to the company's growth by expanding its market reach and validating the efficacy of its technology.

Clinical Laserthermia Systems AB Class B Financial Statement Overview

Summary

Clinical Laserthermia Systems AB Class B is experiencing robust revenue growth but continues to face profitability challenges with consistent losses. The balance sheet is strong with low leverage, but cash flow issues persist due to negative free cash flow, highlighting a dependency on external financing. The company needs to focus on cost management to improve margins and achieve sustainable profitability.

Income Statement

The company has shown significant revenue growth from 2023 to 2024, with a growth rate of approximately 127%. However, the company continues to operate at a loss with negative net income and EBIT margins. The gross profit margin has improved but remains unsatisfactory due to high operational costs leading to negative profits.

Balance Sheet

The company has a strong equity position with a high equity ratio of around 87.5% as of 2024. The debt-to-equity ratio is very low, indicating low leverage. However, the company has consistently negative net income, impacting its return on equity, which is currently negative.

Cash Flow

The company faces challenges in generating positive cash flows with operating cash flow at zero and negative free cash flow in 2024. The financing cash flow is positive due to significant financing activities, reflecting reliance on external funding.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.78M	8.27M	6.27M	2.25M	1.33M
Gross Profit	10.42M	3.00M	-2.79M	-3.63M	876.00K
EBITDA	-44.76M	-68.41M	-57.84M	-54.95M	-51.61M
Net Income	-47.62M	-79.79M	-70.66M	-63.62M	-57.94M
Balance Sheet
Total Assets	78.56M	57.73M	49.51M	66.74M	44.40M
Cash, Cash Equivalents and Short-Term Investments	22.51M	15.33M	10.59M	31.17M	11.87M
Total Debt	224.00K	454.00K	30.68M	273.50K	673.50K
Total Liabilities	12.88M	14.20M	41.64M	45.55M	30.47M
Stockholders Equity	68.72M	45.77M	9.22M	21.79M	13.93M
Cash Flow
Free Cash Flow	-58.92M	-71.95M	-71.25M	-66.73M	-55.76M
Operating Cash Flow	-56.45M	-66.45M	-70.69M	-66.17M	-55.41M
Investing Cash Flow	-7.47M	-5.50M	-886.00K	-408.00K	-508.00K
Financing Cash Flow	71.10M	76.69M	61.84M	85.88M	62.02M

Clinical Laserthermia Systems AB Class B Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Positive. The current price of 6.75 is above the 20-day moving average (MA) of 5.88, above the 50-day MA of 4.56, and above the 200-day MA of 3.71, indicating a bullish trend. The MACD of 0.44 indicates Negative momentum. The RSI at 67.06 is Neutral, neither overbought nor oversold. The STOCH value of 67.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CLS.B.

Clinical Laserthermia Systems AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLS.B	53 Neutral	€174.53M	―	-78.89%	―	57.14%	81.07%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
2OK	―	€5.77M	―	-19.36%	―	―	―
LUR	―	€8.14M	―	-60.20%	―	―	―
7820	―	€7.73M	―		―	―	―
NOSA	46 Neutral	kr192.37M	―		―	44.92%	52.25%
ARCOMA	―	kr121.34M	22.06		―	―	―